文献速递核素与放射性配体治疗肿瘤 PET/CT

神经内分泌肿瘤中177Lu-DOTATATE SPECT/CT与68Ga-DOTATOC PET/CT的SUV参数定量比较:可行性研究

Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该前瞻性可行性研究纳入10例转移性进展期高分化胃肠胰神经内分泌肿瘤患者,在肽受体放射性核素治疗第一周期后行177Lu-DOTATATE SPECT/CT定量,并与治疗前68Ga-DOTATOC PET/CT的SUV参数比较。结果显示病灶Lu-SUV中位值显著低于Ga-SUV,而Lu-MTV、Lu-TLR和Lu-TSR中位值显著高于对应Ga参数;SUV和MTV参数呈强相关,TLR弱相关,TSR中至强相关。提示177Lu-DOTATATE SPECT/CT定量在临床实践中可行,且多个SUV参数与68Ga-DOTATOC PET/CT相应参数强相关。

要点

  • 177Lu-DOTATATE SPECT/CT定量在临床实践中可行。
  • 病灶Lu-SUV中位值显著低于Ga-SUV,Lu-MTV、Lu-TLR、Lu-TSR显著高于对应Ga参数。
  • SUV和MTV参数强相关,TLR弱相关,TSR中至强相关。

核心结论

  • 177Lu-DOTATATE SPECT/CT定量在临床实践中可行,多个SUV参数与68Ga-DOTATOC PET/CT相应参数强相关。

研究设计与样本

  • 前瞻性纳入10例高分化胃肠胰神经内分泌肿瘤患者,均有治疗前68Ga-DOTATOC PET/CT和177Lu-DOTATATE第一周期后SPECT/CT。
  • SPECT/CT系统转换因子为9.48 counts/MBq per second,采用迭代算法和SPECTRA Quant软件定量。
  • 比较生理摄取(肝/脾)、肿瘤摄取(每例1-10个;SUVmax、SUVmean、SUVpeak、MTV)及肿瘤/肝、肿瘤/脾比值。

主要发现

  • 10例患者(8女2男)年龄50-83岁,转移性进展期高分化胃肠胰神经内分泌肿瘤(7例小肠、2例胰腺、1例直肠)。
  • 病灶Lu-SUV中位值显著低于对应Ga-SUV(P < 0.001)。
  • 病灶Lu-MTV、Lu-TLR、Lu-TSR中位值显著高于对应Ga-MTV、Ga-TLR、Ga-TSR(P < 0.02)。
  • SUV和MTV参数的Pearson相关系数强(0.779-0.845),TLR弱(0.365-0.394),TSR中至强(0.676-0.750)。

临床怎么用

  • 可尝试用177Lu-DOTATATE SPECT/CT进行治疗后定量评估,但需注意其SUV和MTV等参数与68Ga-DOTATOC PET/CT存在系统性差异。

局限性

  • 样本量仅10例,为可行性研究,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PATIENTS AND METHODS: Patients with WD-GEP-NET who benefited from a pretherapeutic 68Ga-DOTATOC PET/CT and a 177Lu-DOTATATE SPECT/CT after the cycle 1 of peptide receptor radionuclide therapy were prospectively included. SPECT/CT acquisitions were performed on a system calibrated with a conversion factor of 9.48 counts/MBq per second and were reconstructed with an iterative algorithm allowing quantification using the SPECTRA Quant software (MIM Software, Cleveland, OH). For each patient, different SUV parameters were recorded on both PET/CT (Ga parameters) and SPECT/CT (Lu parameters) for comparison: physiological uptakes (liver/spleen), tumor uptake (1-10/patient; SUVmax, SUVmean, SUVpeak, MTV), tumor-to-liver and tumor-to-spleen ratios according to liver/spleen SUVmax and SUVmean (TLRmax, TLRmean, TSRmax, and TSRmean, respectively). RESULTS: Ten patients (8 female; 2 male) aged from 50 to 83 years presenting with a metastatic progressive WD-GEP-NET (7 small intestine, 2 pancreas, 1 rectum) were included. Median values of lesional Lu-SUV were significantly lower than the corresponding Ga-SUV (P < 0.001), whereas median values of lesional Lu-MTV, Lu-TLR, and Lu-TSR were significantly higher than the corresponding Ga-MTV, Ga-TLR, and Ga-TSR (P < 0.02). Pearson correlation coefficients were strong for both SUV and MTV parameters (0.779-0.845), weak for TLR parameters (0.365-0.394), and moderate-to-strong for TSR parameters (0.676-0.750). CONCLUSIONS: Our results suggest the feasibility of 177Lu-DOTATATE SPECT/CT quantification in clinical practice and show a strong correlation of several SUV-based parameters with the corresponding in 68Ga-DOTATOC PET/CT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thuillier P, Maajem M, Schick U, et al. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study. Clin Nucl Med. 2021. PMID: 33234927. doi:10.1097/RLU.0000000000003412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。